Vaccines

Individuals 12 years and older can now receive the Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) (NVX-CoV2601) to protect against variants that are currently circulating, after receiving an Emergency Use Authorization from the FDA.

*Co-first authorship was earned, as each equally contributed to the methodical and rigorous review of the literature, writing, and editing of this article.

In collaboration with Contemporary Pediatrics, Contemporary OB/GYN, and Contagion, Tina Tan, MD, FAAP, FIDSA, FPIDS, discusses the benefits of having new tools to fight RSV in infants, potential vaccine hesitancy, and RSV trends currently being observed.

Standout updates include a relaxed recommendation for patients with a history of egg allergies, and that all available influenza vaccines for the 2023 to 2024 flu season are quadrivalent.

Bivalent COVID-19 vaccines by both Moderna and Pfizer-BioNTech are no longer authorized for use in the United States.

According to a recent Morbidity and Mortality Weekly Report, the original COVID-19 monovalent and bivalent vaccines helped reduce emergency department or urgent care encounters for children aged 6 months to 5 years.

Basis for a Biologics License Application submission to the FDA is being built for PXVX0317, following topline results demonstrated in a pair of phase 3 trials, including 1 trial featuring adolescents and adults aged 12 to 64 years.

Ervebo has been approved by the FDA to prevent the Ebola virus for individuals aged 12 months and older, after being initially approved for those 18 years and older in 2019.

In unanimous fashion, the FDA AMDAC voted 21 to 0 that nirsevimab has a favorable benefit risk profile for the prevention of RSV lower respiratory tract disease (LRTD) in newborns and infants during their first RSV season.

How much progress have we made in developing therapies to treat this common childhood respiratory disorder?

The vaccine efficacy of the Novavax’s NVX-CoV2373 was 79.5% in adolescents.

Jonathan Miller, MD, pediatrician and chief of primary care, pediatrics, at Nemours Children's Health in the Delaware Valley, spoke about the latest data regarding early HPV vaccination in children as young as 9 at the 2023 Pediatric Academic Societies meeting.

According to Pfizer, the company’s pneumococcal conjugate vaccine Prevnar 20 has been approved by the FDA to treat infants and children aged 6 weeks to 17 years for the prevention of invasive pneumococcal disease (IPD).

Monovalent vaccines by these manufacturers are no longer authorized for use in the United States.

Tina Tan, MD, and Sean O’Leary, MD, discuss the future of COVID-19 vaccines and the possibility of a combination vaccine.

Tina Tan, MD, and Sean O’Leary, MD, give examples of how to address parental hesitancy to vaccinate children against COVID-19.

Sean O’Leary, MD, shares his approach to addressing respiratory infections that are cocirculating with COVID-19 and which viruses clinicians should test for in children.

Experts in pediatrics review current COVID-19 vaccination guidelines, recommendations for dose intervals, and barriers to vaccinating children.

In a recent study, vaccination administered during pregnancy was effective against severe lower respiratory tract illness associated with respiratory syncytial virus (RSV) in infants.

A multi-country survey revealed 50% of meningitis vaccination appointments were delayed or canceled amid the COVID-19 pandemic, highlighting the need for “urgent action” to maintain routine vaccination levels among children, according to survey authors.

In a recent review, children with vaccination against human papillomavirus (HPV) initialized at a younger age were more likely to receive their full vaccination series.

If approved by the FDA, this 5-in-1 investigational candidate could provide the broadest meningococcal serogroup coverage.

At the 44th National Association of Pediatric Nurse Practitioners Conference, the CDC provided an updated immunization schedule, detailing new changes.

A new booster shot of the Pfizer-BioNTech COVID-19 vaccine is now available for young children to help protect this population against serious COVID-19 effects.

In a recent study, children aged 5 to 11 years were less likely to be hospitalized with the Omicron strand if they received vaccination against COVID-19.